Navigation Links
UAB study examines hearing loss, Viagra use
Date:5/18/2010

BIRMINGHAM, Ala. Research by a University of Alabama at Birmingham (UAB) professor shows an association between hearing loss and the use of the erectile dysfunction drug Viagra.

Findings published May 18 in Archives of Otolaryngology-Head and Neck Surgery indicate a potential for long-term hearing loss following use of Viagra, and possibly following use of other phosphodiesterase type 5 inhibitors (PDE-5i) drugs such as Cialis and Levitra, although results on those drugs are inconclusive.

"It appears from these findings that the current government warning regarding hearing loss and the use of PDE-5i medications is warranted," said study author Gerald McGwin, Ph.D., a professor of epidemiology in the UAB School of Public Health. "Though there are limitations to this study, it is prudent that patients using these medications be warned about the signs and symptoms of hearing impairment and be encouraged to seek immediate medical attention to potentially forestall permanent damage."

In 2007, following the report of several case studies potentially linking PDE-5i use and sudden hearing loss, the Food and Drug Administration announced labeling changes for PDE-5i medications so that the risk of hearing problems was more prominently displayed. McGwin said this is the first epidemiologic study to evaluate the relationship between PDE-5i drugs and long-term hearing loss.

McGwin examined data on 11,525 men over 40 years of age gathered by the Medical Expenditure Panel Survey, a survey conducted by the federal Agency for Healthcare Research and Quality between 2003 and 2006. Men who reported use of PDE-5i medications were twice as likely to also report hearing loss as were men who had not used the drugs.

McGwin said the relationship was strongest for men reporting use of sildenafil (Viagra) over those who used tadalafil (Cialis) or vardenafil (Levitra), a finding he attributed in part to a small sample size for both of the latter drugs. McGwin said the findings indicated an elevated but not statistically significant increase in hearing loss for users of tadalafil and vardenafil.

PDE-5i drugs were originally designed to treat pulmonary hypertension and are now used extensively in the treatment of erectile dysfunction (ED). McGwin said one important consideration in evaluating the nature of the relationship between the drugs and hearing is the existence of a plausible biological mechanism of how these drugs might cause hearing loss.

"PDE-5i medications work in ED patients by their ability to increase blood flow to certain tissues in the body," said McGwin. "It has been hypothesized that they may have a similar effect on similar tissues in the ear, where an increase of blood flow could potentially cause damage leading to hearing loss."

McGwin acknowledged limitations in the study, including the limited sample size for tadalafil and vardenafil, concerns over under-reporting of use of PDE-5i medications and confounding factors such as pre-existing conditions that might also contribute to hearing loss. He suggested that additional research regarding the risk from PDE-5i is necessary due to the largely irreversible nature of hearing loss and its impact on quality of life.

"The results of the current study in conjunction with a plausible biologic mechanism lend support to the FDA's decision to warn patients about the potential risk posed by PDE-5i use," he said.


'/>"/>

Contact: Bob Shepard
bshep@uab.edu
205-934-8934
University of Alabama at Birmingham
Source:Eurekalert

Related medicine news :

1. Study finds 2 sling surgeries equally effective for bladder control in women
2. Newborn infants learn while asleep; study may lead to later disability tests
3. Worlds biggest study on cell phones and brain cancer inconclusive
4. Varicose vein study shows radiofrequency ablation causes less post-operative pain
5. Independent Study Reveals Family Bonds made Stronger on Vacations where Animals are Involved
6. Lifestyle factors significantly impact survival of non-Hodgkins lymphoma patients, study finds
7. Study identifies 1 of the mechanisms behind breast cancer metastasis
8. Study shows costs and benefits of testosterone in birds
9. Study finds rotavirus vaccine greatly reduces hospitalizations for acute gastroenteritis in children
10. Childhood psychological problems create long-term economic losses, study finds
11. HIRC Research Alert: New Study Identifies Best Pharmaceutical Company Account Managers and Program Offerings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Ulster University, Magee Campus ... from 9 am to 3 pm to present to graduate students exciting new and ... an original curriculum project led by The Health Improvement Service of the Western Health ...
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, ... families and business owners in North Central West Virginia, is embarking on a ... differently abled residents in the region. , The Stepping Stones organization offers a ...
(Date:6/22/2017)... Indianapolis, IN (PRWEB) , ... June 22, 2017 ... ... employee benefits advisory organization, is pleased to welcome Whipple & Company as its ... on the clear purpose of balancing their clients’ risk while tailoring optimized benefit ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... awards for environmental excellence. Maryland Recycling Network has awarded the Baltimore VA Medical ... Outstanding Small Government Program Award for its efforts to promote waste reduction and ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... that Claritas Capital, a Nashville-based private equity firm, has invested $3.35 million in ... for some time, and Claritas Capital offers the smart money, speed to market ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... 8, 2017  Less than a month ago, amateur ... 200,000 companies, including hospital networks, in over 150 countries. ... of the largest online extortion attempts ever recorded. With ... it is imperative that providers understand where the risks ... this — and many other very real cyber threats.  ...
(Date:6/7/2017)... GAITHERSBURG, Md. , June 7, 2017  Novavax, Inc., ... the second of two Phase 2 trials of its RSV ... women of child bearing age have been published in the ... this publication have been shared in prior scientific conferences). The ... trial in April 2014. Novavax is developing the RSV F ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
Breaking Medicine Technology: